Course Description
This webinar focuses on important factors related to use of LAIs for substance use disorders, such as target patient populations, indications, product preparation, dosing, administration techniques, adverse effects, storage requirements, and monitoring recommendations.
Learning Objectives
- Describe dosing and administration, including product preparation, for naltrexone long acting injectable (LAI) and buprenorphine LAI.
- Identify contraindications, warnings/precautions, common adverse effects and potential mitigation strategies for naltrexone LAI and buprenorphine LAI.
- Describe the storage requirements and stability data of naltrexone LAI and buprenorphine LAI.
- Outline a plan for monitoring and follow up of a patient receiving naltrexone LAI or buprenorphine LAI.
Target Audience
We invite you to participate in this online course if you are a pharmacist, nurse, or other health care professional interested in administering and/or learning more about psychotropic long-acting injectables for patients living with serious mental illness or substance use disorders.
Faculty
View biographical information
Benjamin Miskle, MBA, PharmD
Clinical Assistant Professor, University of Iowa Carver College of Medicine and College of Pharmacy
Benjamin Miskle, PharmD, is a Clinical Assistant Professor in the University of Iowa Carver College of Medicine, Department of Psychiatry, and the University of Iowa College of Pharmacy. He earned his Doctor of Pharmacy degree from the University of Missouri–Kansas City and completed both a PGY 1 Pharmacy Practice Residency and a PGY 2 Psychiatric Pharmacy Residency at the Chillicothe Veterans Affairs Medical Center.
Dr. Miskle practices in outpatient psychiatry with a clinical focus in Addiction Medicine, including medications for substance use disorders such as extended release naltrexone and long acting injectable buprenorphine. He serves as Assistant Director of the Advanced Practice Provider Fellowship in Addiction Medicine and Co Director of the Psychopharmacology Didactic Series for Psychiatry Residents, and provides care across addiction medicine walk in clinics, mobile MAT services, and interdisciplinary psychiatry settings. His scholarly and grant funded work focuses on improving access to evidence based addiction treatment, harm reduction, and integrated care models. Dr. Miskle has received multiple awards, including the Iowa Pharmacy Association’s Excellence in Innovation Award and Faculty Preceptor of the Year, and has led statewide initiatives such as the Naloxone in Schools (IA-NEXT), expansion of hepatitis C and HIV testing and treatment with SUD programs (iACCESS), and substance use disorder training expansion (RISE IA) projects. He is an active member of the Iowa Pharmacy Association and the American Association of Psychiatric Pharmacists and regularly delivers continuing education on medications for opioid and alcohol use disorders.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Complete the pre-test (if applicable) before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete the evaluation at the end of the activity.
- If necessary, complete the post-test retest no later than the closing activity date.
- Receive a passing grade (70%).
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 06/01/2026-06/01/2029
ACPE Contact Hours: 0.75
ACPE Number: 0284-0000-26-045-H01-P (Knowledge)
 | The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
View Faculty, Program Planning Committee/Reviewers Disclosures of Interest
Faculty: Benjamin Miskle, MBA, PharmD discloses: Stock(s) - Johnson & Johnson
Planning Committee/Peer Reviewers:
- Andria F. Church, PharmD, BCPP has nothing to disclose
- Beth DeJongh, PharmD, FAAPP, BCPP, BCPS has nothing to disclose
*All identified conflicts of interest have been mitigated.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
This activity is supported by an educational grant from Johnson & Johnson.